An endogenous TNF-α antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models

Molecular Therapy

Volumn 16, Issue 7, 2008, Pages 1316-1322

  Graziewicz, Maria A ^a   Tarrant, Teresa K ^b   Buckley, Brian ^a   Roberts, Jennifer ^b,c   Fulton, LeShara ^b,c   Hansen, Henrik ^d   Ørum, Henrik ^d   Kole, Ryszard ^a,b,c   Sazani, Peter ^a  

^a Ercole Biotech   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Santaris Pharma AS   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETANERCEPT; LOCKED NUCLEIC ACID; MESSENGER RNA PRECURSOR; OLIGONUCLEOTIDE; SPLICE SWITCHING OLIGONUCLEOTIDE; SSO 3083; SSO 3274; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; EXON; GENE EXPRESSION REGULATION; HEPATITIS; HUMAN; HUMAN CELL; LIVER PROTECTION; MAINTENANCE DRUG DOSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RNA SPLICING; SINGLE DRUG DOSE; UPREGULATION;

MUS;

EID: 45749096229     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.85     Document Type: Article

References (42)

1. Palladino, MA, Bahjat, FR, Theodorakis, EA and Moldawer, LL (2003). Anti-TNF-alpha therapies: The next generation. Nat Rev Drug Discov 2: 736-746.
2. Gaffo, A, Saag, KG and Curtis, JR (2006). Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63: 2451-2465.
3. Lainez, B, Fernandez-Real, JM, Romero, X, Esplugues, E, Canete, JD, Ricart, W et al. (2004). Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. Int Immunol 16: 169-177.
4. Sazani, P, Graziewicz, M and Kole, R (2007). Splice switching oligonucleotides as potential therapeutics. In: Crooke, ST (ed.). Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. CRC Press: Boca Raton, FL. pp. 89-114.
5. Wood, M, Yin, H and McClorey, G (2007). Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 3: E109.
6. Eckstein, F (2007). The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 7: 1021-1034.
7. Aartsma-Rus, A and van Ommen, GJ (2007). Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA 13: 1609-1624.
8. Khoo, B, Roca, X, Chew, SL and Krainer, AR (2007). Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol Biol 8: 3.
9. Williams, T and Kole, R (2006). Analysis of prostate-specific membrane antigen splice variants in LNCap cells. Oligonucleotides 16: 186-195.
10. Siwkowski, AM, Malik L, Esau, CC, Maier, MA, Wancewicz, EV, Albertshofer, K et al. (2004). Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res 32: 2695-2706.
11. Suwanmanee, T, Sierakowska, H, Fucharoen, S and Kok, R (2002). Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/ HbE disorder. Mol Ther 6: 718-726.
12. Cartegni, L and Krainer, AR (2003). Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 10: 120-125.
13. Kalbfuss, B, Mabon, SA and Misteli, T (2001). Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J Biol Chem 276: 42986-42993.
14. Scaffidi, P and Misteli, T (2005). Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11: 440-445.
15. Moulton, HM, Fletcher, S, Neuman, BW, McClorey, G, Stein, DA, Abes, S et al. (2007). Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 35 826-828.
16. Wheeler, TM, Lueck, JD, Swanson, MS, Dirksen, RT and Thornton, CA (2007). Correction of CIC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117: 3952-3957.
17. Sazani, P, Gemignani, F, Kang, SH, Maier, MA, Manoharan, M, Persmark, M et al. (2002). Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat Biotechnol 20 1228-1233.
18. Alter; J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino, oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177.
19. Lu, QL, Mann, CJ, Lou, F, Bou-Gharios, G, Morris, GE, Xue, SA et al. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9: 1009-1014.
20. Vickers, TA, Zhang, H, Graham, MJ, Lemonidis, KM, Zhao, C and Dean, NM (2006). Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide. J Immunol 176: 3652-3661.
21. van Deutekom, JC, Janson, AA, Ginjaar, IB, Frankhuizen, WS, Aartsma-Rus, A, Bremmer-Bout, M et al. (2007). Local dystrophin restoration with antisense oligonucleoticle PRO051. N Engl J Med 357: 2677-2686.
22. Roberts, J, Palma, E, Sazani, P, Ørum, H, Cho, M and Kole, R (2006). Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 14:471-475.
23. Wallach, D, Holtmann, H, Engelmann, H and Nophar, Y (1988). Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol 140: 2994-2999.
24. Brand, DD, Latham, KA and Rosloniec, EF (2007). Collagen-induced arthritis. Nat Protoc 2: 1269-1275.
25. Moosmayer, D, Wajant, H, Gerlach, E, Schmidt, M, Brocks, B and Pfizenmaier, K (1996). Characterization of different soluble TNF receptor (TNFR80) derivatives: Positive influence of the intracellular domain on receptor/ligand interaction and TNF neutralization capacity. J Interferon Cytokine Res 16: 471-477.
26. Keppler, DO, Rudigier, JF, Bischoff, E and Decker, KF (1970). The trapping of uridine phosphates by D-galactosamine. D-glucosamine, and 2-deoxy-D-galactose. A study on the mechanism of galactosamine hepatitis. Eur J Biochem 17: 246-253.
27. Zang, GQ Zhou, XQ Yu, H, Xie, Q, Zhao, GM, Wang, B et al. (2000). Effect of hepatocyte apoptosis induced by TNF-alpha on acute severe hepatitis in mouse models. World J Gastroenterol 6: 688-692.
28. Wang, Y, Singh, R, Lefkowitch, JH, Rigoli, RM and Czaja, MJ (2006). Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 281: 15258-15267.
29. Kallinowski, B, Haseroth, K, Marinos, G, Hanck, C, Stremmel, W, Theilmann, L et al. (1998). Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C Virus (HCV) infection. Clin Exp Immunol 111: 269-277.
30. Spengler, U, Zachoval, R, Gallati, H, Jung, MC, Hoffmann, R, Riethmuller, G et al. (1996). Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases. Cytokine 8: 864-872.
31. Wooley, PH, Dutcher, J, Widmer, MB and Gillis, S (1993). Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602-6607.
32. Fluiter, K, ten Asbroek, AL, de Wissel, MB, Jakobs, ME, Wissenbach, M, Olsson, H et al. (2003). In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res 31: 953-962.
33. Kastelein, JJ, Wedel, MK, Baker, BF, Su, J, Bradley, JD, Yu, RZ et al. (2006). Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114: 1729-1735.
34. Rindfleisch, JA and Muller, D (2005). Diagnosis and management of rheumatoid arthritis. Am Fam Physician 72: 1037-1047.
35. Konttinen, YT, Seitsalo, S, Lehto, M and Santavirta, S (2005). Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs. Acta Orthop 76: 614-619.
36. Wee, S, Pascual, M, Eason, JD, Schoenfeld, DA, Phelan, J, Boskovic, S et al. (1997). Biological effects and fate of a soluble, dimeric, 80-kDa tumor necrosis factor receptor in renal transplant recipients who receive OKT3 therapy. Transplantation 63: 570-577.
37. Plessner, HL, Lin, PL, Kohno, T, Louie, JS, Kirschner, D, Chan, J et al. (2007). Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195: 1643-1650.
38. Tillman, LG, Geary, RS and Hardee, GE (2007). Oral delivery of antisense oligonucleotides in man. J Pharm Sci 97: 225-236.
39. Pincus, T, O'Dell, JR and Kremer, JM (1999). Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 131: 768-774.
40. Olsen, NJ and Stein, CM (2004). New drugs for rheumatoid arthritis. N Engl J Med 350: 2167-2179.
41. Swayze, EE, Siwkowski, AM, Wancewicz, EV, Migawa, MT, Wyrzykiewicz, TK, Hung, G et al. (2007). Antisense oligonucleotides containing lacked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35: 687-700.
42. Elmén, J, Lindow, M, Schütz, S, Lawrence, M, Petri, A, Obad, S et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452: 896-899.